10:40 AM EST, 11/05/2024 (MT Newswires) -- ZyVersa Therapeutics ( ZVSA ) said Tuesday that recently published data show inflammasome inhibition may protect pancreatic islet beta cells and reduce progression from obesity to insulin resistance and type 2 diabetes.

ZyVersa's Inflammasome ASC Inhibitor IC 100 aims to reduce obesity-related inflammation by inhibiting inflammasome adaptor protein ASC, the company said.

"This data supports the potential of Inflammasome ASC Inhibitor IC 100, as a key component of obesity care when added to incretins used for weight loss," the company said, adding that it plans to initiate phase 1 trials of IC 100 in mid-2025.

Shares of ZyVersa rose more than 37% in recent trading.

Price: 2.60, Change: +0.77, Percent Change: +42.02